Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.

PloS one - 1 Jan 2015

Devapatla Bharat, Sharma Ankur, Woo Sukyung

Abstract excerpt

Antiangiogenic therapy is important for the treatment of gynecological cancer. However, the therapeutic benefit derived from these treatments is transient, predominantly due to the selective activation of compensatory proangiogenic pathways that lead to rapid development of resistance. We aimed to identify and target potential alternative signaling to anti-vascular endothelial growth factor (VEGF) therapy, with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Human Umbilical Vein Endothelial Cells
Share to Neovascularization, Pathologic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to Phenylurea Compounds

Share to Receptors, Interleukin-8B

Share to Sorafenib

Share to Vascular Endothelial Growth Factor A

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26414070
DOI: 10.1371/journal.pone.0139237
PMCID: PMC4587670

Genes

CXCR2
CXCL8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.PMID 26414070Read ↗

Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells.Semantic proximity Read ↗

A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignanciesSemantic proximity Read ↗

Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.Semantic proximity Read ↗

Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells.Semantic proximity Read ↗

CCL2-CCR2 Axis Inhibition in Osteosarcoma Cell Model: The Impact of Oxygen Level on Cell Phenotype.Semantic proximity Read ↗

Mesenchymal stromal cells release CXCL1/2/8 and induce chemoresistance and macrophage polarizationSemantic proximity Read ↗

Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targetingSemantic proximity Read ↗

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer CellsSemantic proximity Read ↗

Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy ResistanceSemantic proximity Read ↗

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.Semantic proximity Read ↗

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanismsSemantic proximity Read ↗

VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation of BRCA1 and BRCA2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.